Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MONO-LINYAH vs DEMULEN 1/35-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
Moderate to severe plaque psoriasis,Psoriatic arthritis,Ankylosing spondylitis,Non-radiographic axial spondyloarthritis
Prevention of pregnancy
10 mg orally once daily
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life is 3–5 hours in adults; prolonged to 8–15 hours in renal impairment (Cr Cl <30 m L/min) and in neonates.
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
Metabolized via general protein degradation pathways; not primarily metabolized by CYP450 enzymes.
Ethinylestradiol undergoes hepatic metabolism via CYP3A4; norethindrone undergoes reduction and conjugation in the liver.
Predominantly renal as unchanged drug (≥90%); minor biliary/fecal (<5%).
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
20–30% bound to albumin.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 93% bound to albumin and SHBG.
0.5–0.8 L/kg, consistent with distribution into total body water; increased in edema or ascites.
Ethinyl estradiol: 2.3-4.3 L/kg; norethindrone: 4.4 L/kg; indicates extensive tissue distribution.
Oral bioavailability is 60–70% (first-pass metabolism ~30–40%); immediate-release tablets.
Ethinyl estradiol: 40-45% (oral; first-pass metabolism); norethindrone: 64-67% (oral).
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min: not recommended
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Avoid use if liver function tests are abnormal.
Weight <20 kg: 2.5 mg once daily; 20-40 kg: 5 mg once daily; >40 kg: 10 mg once daily
Not indicated for use before menarche. For postmenarchal adolescents, use same dosing as adults (one tablet orally once daily).
Start at 5 mg once daily; titrate based on response and tolerability
Not indicated for use in postmenopausal women.
None
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and smoking intensity. Women over 35 who smoke should not use this product.
Increased risk of infections,Hypersensitivity reactions,Hepatotoxicity,Inflammatory bowel disease exacerbation
Increased risk of thromboembolic disorders,Cerebrovascular disease,Myocardial infarction,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate/lipid effects,Headache,Uterine bleeding,Ocular lesions,Depression
Hypersensitivity to active substance or excipients,Clinically significant active infection
Known or suspected pregnancy,Current or past thrombosis,Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms,Major surgery with prolonged immobilization,Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenomas or carcinomas,Active liver disease,Known hypersensitivity to any component
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically meaningful. Avoid excessive alcohol as it may impair liver function.
No significant food interactions. Grapefruit juice has minimal effect on ethinyl estradiol; no restriction needed. Avoid excessive alcohol, which may impair adherence or increase liver enzymes. St. John's wort reduces contraceptive efficacy and should be avoided.
Pregnancy Category X. First trimester: High risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: Risk of oligohydramnios, fetal renal impairment, and neonatal anuria. Contraindicated in all trimesters.
First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and oral clefts (OR ~1.3-1.6). Second/third trimester: Androgenization of female fetus (clitoromegaly, labial fusion) due to progestin component; possible association with hypospadias in males with first-trimester exposure. Avoid use in pregnancy.
Excreted in human milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., renal toxicity), breast-feeding is contraindicated during therapy and for at least 30 days after last dose.
Excreted in breast milk; estimated infant dose <1% of maternal dose. M/P ratio not available for ethinyl estradiol/ethynodiol diacetate. May reduce milk production and quality. Use only if benefits outweigh risks; lowest effective dose recommended.
Not applicable; contraindicated in pregnancy. If inadvertent exposure, immediate discontinuation is required; no dose adjustment is recommended as alternative therapy should be initiated.
Contraindicated in pregnancy; no dose adjustment applicable. If inadvertently used, discontinue immediately.
Mono-Linyah (ethinyl estradiol and norgestimate) is a combined oral contraceptive. Counsel patients about the increased risk of venous thromboembolism (VTE), especially in smokers over 35. Missed pill instructions vary by how many are missed. Consider drug interactions with rifampin, certain anticonvulsants (e.g., carbamazepine, phenytoin), and St. John's Wort, which may reduce efficacy. Use with caution in patients with a history of migraine with aura, as it may increase stroke risk.
DEMULEN 1/35-28 (ethinyl estradiol 35 mcg + ethynodiol diacetate 1 mg) is a monophasic combined oral contraceptive. Its progestin has mild androgenic activity, which may be less favorable for acne-prone patients compared to third-generation pills. The 28-day pack includes 21 active pills and 7 inert pills. Counsel patients to take at the same time daily; missed pills increase breakthrough bleeding and pregnancy risk. It may be used off-label for cycle control in patients without contraindications.
Take one pill daily at the same time each day to maintain effective hormone levels.,If you miss a pill, follow the package insert instructions or consult your healthcare provider.,Use a backup contraceptive method (e.g., condoms) if you miss pills or if you have vomiting or severe diarrhea.,This medication does not protect against HIV or other sexually transmitted infections.,Smoking while using this pill increases your risk of serious cardiovascular events; do not smoke.,Contact your healthcare provider if you experience leg pain/swelling, chest pain, shortness of breath, or severe headache.
Take one pill daily at the same time, preferably after dinner to reduce nausea.,If you miss one pill, take it as soon as remembered; if missed more than one, use backup contraception for 7 days.,Smoking increases risk of blood clots; especially dangerous if over 35 and smokes.,Some antibiotics (e.g., rifampin) and antiseizure medications may reduce effectiveness.,Report any signs of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,Breakthrough bleeding is common in first 3 cycles; if persistent, contact your healthcare provider.,Do not use if pregnant; if pregnancy occurs, stop immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MONO-LINYAH vs DEMULEN 1/35-28, answered by our medical review team.
MONO-LINYAH is a Combination Oral Contraceptive that works by Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.. DEMULEN 1/35-28 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MONO-LINYAH and DEMULEN 1/35-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MONO-LINYAH is: 10 mg orally once daily. The standard adult dose of DEMULEN 1/35-28 is: One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MONO-LINYAH and DEMULEN 1/35-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MONO-LINYAH is classified as Category C. Pregnancy Category X. First trimester: High risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: Risk of oligohydr. DEMULEN 1/35-28 is classified as Category C. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and oral clefts (OR ~1.3-1.6). Second/third trimester: Androgenization of female fetus (clitoromeg. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.